Thanks for sharing. @MDAndersonNews experience of multivisceral en bloc resection for metastatic adrenocortical carcinoma. May be an option for selected pts, but requires careful selection and should be performed by highly experienced multidisciplinary teams.

Completed endocrine surg fellowship at @MDAndersonNews this week. Thankful for countless lessons learned both in and out of the OR from this incredible group. Slowly making my way back to MN & looking fwd to a year as HPB fellow @IU_Surgery before returning to @MayoClinicSurg.

🆕MEN-1 recommendations - screening & management of PTH, pituitary & #NETs 🔑for duo/pan-NETs ✔️initial SSTR-PET in all ✔️<2cm and <1mm growth 👉🏻observe q 1-2 yrs ✔️no routine eus Consider genetic testing🧬 if new PanNETs <40 yo👉🏻is it realistic? 🔗 https://t.co/O02D0JhxIs

Had a great time at #ENDO2025 in San Francisco presenting on the management of primary hyperparathyroidism in MEN1 and the recent best practice guidelines. Honored to share the podium with mentors. @TheEndoSociety

Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice https://t.co/VQi1nMc9ud 55 clinical recommendations developed to guide clinicians, patients, and stakeholders about approaches for MEN1 in adults and children.

I am also profoundly grateful for the opportunity to be an invited co-author of this manuscript with true global leaders in the fields of endocrinology & oncology, who have been profoundly welcoming to me since my diagnosis in 2009 and entry into advocacy shortly thereafter 🙏

As a patient, parent, and physician (my own “3 Ps” of MEN1) I tried to impart my personal perspective to these guidelines, which I hope will be helpful to any clinicians treating the syndrome but most of all to families trying to mitigate the lifelong risk of hereditary tumors

I still get excited about good clinical papers! 😀I have been waiting for this one with much anticipation... For anyone taking care of patients with MEN1 or interested in learning more, this is the document you need. Kudos to the team that got this done including @marklewismd !

@OmairShariq @TheLancetEndo @TheEndoSociety The release of the 2025 international guidelines for MEN1 marks a significant advancement in the field of endocrinology. Given the comprehensive 55 recommendations, it will be interesting to see how these guidelines influence current clinical practices globally in comparison to

Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice - The Lancet Diabetes & Endocrinology🔴✅

🌍 Thank you to the global MEN1 Delphi Panel & co-authors across 22 countries and 5 continents - a truly international effort that we hope will improve outcomes for patients with this rare and complex syndrome. #MEN1 #CureNETs @RareDiseases

📖 Also see our companion systematic review & meta-analysis that informed the guidelines: https://t.co/8f7WingweV

🆕 What’s new in the 2025 MEN1 guidelines? • Revised age-based screening intervals • Further detail re: surveillance and management of MEN1 PNETs • Updated parathyroidectomy guidance • Dedicated pediatric screening pathway • Clinical flowcharts & decision trees 📚 And more…

🚨 The 2025 international guidelines for MEN1 are now published in @TheLancetEndo! 🔄 They succeed the widely cited 2012 JCEM guidelines @TheEndoSociety ✅ 55 evidence- and consensus-based recommendations 🔓 Free to read: https://t.co/UX10mrDHD4

🆕 What’s new in the 2025 guidelines? • Revised age-based screening intervals • More detail regarding surveillance and management of MEN1 PNETs • Updated parathyroidectomy guidance • Dedicated pediatric screening pathway • Clinical flowcharts & decision trees 📚 And more…

New—Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice https://t.co/Zb8Y3OPztG #MEN1 #FREE to read with registration (also FREE)

@TheAAES Great points!

Thanks for giving us a forum to present this work @TheAAES. Bottom line: selection bias notwithstanding, surgical resection of the primary tumor may confer a survival benefit in *selected* patients with metastatic ACC. #AAES2025

After: 1 year as prelim intern + 5 years as a categorical resident + 4 years of MSc & PhD… Delighted to finally be a US board-certified general surgeon. Grateful to mentors & family who supported me and relieved to finally be done with high-stakes exams…@MayoSurgery @AmBdSurg

“Approach to the Patient: Hereditary Medullary Thyroid Carcinoma” - J Clin Endocrinol Metab 2025: https://t.co/Kec3dyQ9mU Looking for an update on hereditary MTC? We wrote this article to highlight the changing landscape of clinical decision-making & management of this disease.